Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension
CARDIOLOGY IN THE YOUNG, vol.28, no.4, pp.542-547, 2018 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 28 Issue: 4
- Publication Date: 2018
- Doi Number: 10.1017/s1047951117002542
- Journal Name: CARDIOLOGY IN THE YOUNG
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.542-547
- Hacettepe University Affiliated: Yes
Abstract
Background Macitentan is an orally active, potent, dual endothelin receptor antagonist and is the only registered treatment for pulmonary arterial hypertension that significantly reduced morbidity and mortality in a long-term event-driven study.